FDA decision: Oveporexton by Takeda (in 2026)

·Finance

United StatesJapan

If the FDA's decision on Oveporexton by Takeda in 2026 is A full approval or an accelerated approval, the market resolves to Yes.

This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued.